1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

AbbVie’s Stalling Tactics On Humira Pay Off – In More Ways Than One

 
• By Michael McCaughan

A US House hearing focused on long-standing criticism of AbbVie for its ability to delay biosimilar competition for Humira. AbbVie was also able to delay the hearing, and that also seemed to work out well for the company.

Richard Gonzalez may expect delays. Photo illustration/Alamy, Getty
Richard Gonzalez may actually enjoy this kind of traffic. • Source: photo illustration/Alamy, Getty

He who hesitates may be lost, but when it comes to testifying about drug pricing, it appears that there is some benefit in putting it off as long as possible.

For AbbVie Inc., at least, it appears to have worked out that way after the company’s CEO, Richard Gonzalez,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

Lilly’s Direct-To-Consumer Portal Implicated In Texas Anti-Kickback Suit

 
• By Cathy Kelly

Complaint names LillyDirect in action targeting the company’s free nurse and reimbursement support programs for health care providers.

Lilly’s Price Deal For Mounjaro In UK A Harbinger Of The MFN Future?

 
• By Cathy Kelly

The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.

With Thyroid Petition Win, AbbVie Snares Itself; US FDA Sets Up Another Compounding Fight

 
• By Manas Mishra

AbbVie didn’t get everything it sought from a citizen petition but may still have the upper hand over smaller rivals after FDA gives makers of animal-derived thyroid medications a year to seek approval. If the agency removes compounded products, it could face more pricing pushback.

Could Study Questioning GLP-1 Cost Savings Impact CMMI Demo Chances?

 
• By Cathy Kelly

The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.

More from Market Access

BioMarin Fights Back After NICE Blocks English Funding For £500K Batten Disease Drug

 
• By Neena Brizmohun

The health technology assessment institute, NICE, said the price BioMarin was asking for Brineura was too high, even though its appraisal committee applied a cost-effectiveness threshold ten times higher than usual.

Dutch HTA Calls For “Socially Acceptable” Price For Gene Editing Therapy Casgevy

 
• By Francesca Bruce

Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.

Lilly’s Price Deal For Mounjaro In UK A Harbinger Of The MFN Future?

 
• By Cathy Kelly

The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.